[{"AccountsPayableCurrent_0_Q1_USD":905000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":0.0,"ShortTermInvestments_0_Q1_USD":0.0,"OtherAssetsMiscellaneous_0_Q1_USD":238000.0,"IncreaseDecreaseInOperatingLiabilities_1_Q1_USD":-4756000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":81149000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-12186000.0,"RepaymentsOfLongTermDebt_1_Q1_USD":1333000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-12186000.0,"LongTermDebtCurrent_0_Q1_USD":4812000.0,"OtherCostAndExpenseOperating_1_Q1_USD":4200000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":0.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q1_USD":0.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-12186000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":1167000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":15470000.0,"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1_Q1_USD":3000.0,"OtherAssetsNoncurrent_0_Q1_USD":4240000.0,"OtherLiabilitiesCurrent_0_Q1_USD":2123000.0,"NonoperatingIncomeExpense_1_Q1_USD":-255000.0,"DepositsAssetsNoncurrent_0_Q1_USD":194000.0,"ProceedsFromIssuanceOrSaleOfEquity_0_Q1_USD":60000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":0.0,"RestructuringCharges_1_Q1_USD":0.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q1_USD":3264000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1_Q1_USD":2500000.0,"ProceedsFromCollaborators_1_Q1_USD":0.0,"PaymentsOfStockIssuanceCosts_1_Q1_USD":0.0,"OtherSundryLiabilities_0_Q1_USD":375000.0,"OtherNoncashIncomeExpense_1_Q1_USD":38000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q1_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":3088000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":2480000.0,"InvestmentIncomeNet_1_Q1_USD":119000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":50005000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q1_USD":81100000.0,"AmortizationOfFinancingCostsAndDiscounts_1_Q1_USD":130000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":-77000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":4295000.0,"ValueAddedTaxReceivable_0_Q1_EUR":3900000.0,"MinorityInterest_0_Q1_USD":-5758000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q1_USD":22384000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":2500000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":57947000.0,"LiabilitiesCurrent_0_Q1_USD":14405000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":87981000.0,"Liabilities_0_Q1_USD":21952000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":-1038000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.2,"CostsAndExpenses_1_Q1_USD":11931000.0,"CommonStockValue_0_Q1_USD":74000.0,"CommonStockSharesOutstanding_0_Q1_shares":73681593.0,"CommonStockSharesIssued_0_Q1_shares":73681593.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":81149000.0,"AssetsCurrent_0_Q1_USD":82639000.0,"Assets_0_Q1_USD":87981000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":29600000.0,"AdditionalPaidInCapital_0_Q1_USD":2315810000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-11993000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-10442000.0,"LongTermDebtNoncurrent_0_Q1_USD":3252000.0,"NetIncomeLoss_1_Q1_USD":-12186000.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":59280000.0,"ShareBasedCompensation_1_Q1_USD":1167000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":4467000.0,"PreferredStockSharesAuthorized_0_Q1_shares":33333.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"OperatingIncomeLoss_1_Q1_USD":-11931000.0,"InterestPaidNet_1_Q1_USD":179000.0,"InterestExpense_1_Q1_USD":167000.0,"DepreciationAndAmortization_1_Q1_USD":133000.0,"CommonStockSharesAuthorized_0_Q1_shares":131500000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":6565000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":62461000.0,"StockholdersEquity_0_Q1_USD":28142000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-2275749000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":1102000.0,"ProfitLoss_1_Q1_USD":-12186000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":1490000.0,"ValueAddedTaxReceivableNoncurrent_0_Q1_USD":0.0,"Ticker":"CTIC","CIK":"891293","name":"CTI BIOPHARMA CORP","OfficialName":"CTI BioPharma Corp. (DE) Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"472610380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200515"}]